Rongchang Pharmaceutical

Founded in 1993, Rongchang Group comprises Rongchang Pharmaceutical, Rongchang Bio (stock code: 9995.HK), MabPlex, Rongchang Zibo, and Yeda Incubation Center, integrating R&D, production, sales, and services, and spanning four major fields: modern Chinese medicine, biopharmaceuticals, biopharmaceutical R&D and manufacturing services (CDMO), and incubation of biomedical enterprises and projects.
In the field of Chinese medicine, the company holds over 90 drug production approvals. Among them, the flagship products are the Gantai and Tianmeng series. In addition, Jiannaobusu Pills, Daqingye series, Shiwei, Xiao'er Dingchuan Oral Liquid, Kunning Oral Liquid, and Compound Jingjie Fumigation Lotion are also well received in the market.
In the biopharmaceutical field, the company is committed to discovering, developing, and commercializing first-in-class and best-in-class biopharmaceuticals, creating a number of innovative biological drugs with significant clinical value for major diseases such as autoimmunity, tumors, and ophthalmology. The company has an R&D and management team led by senior experts and has undertaken more than ten national 'Major New Drug Innovation' science and technology projects and national '863' projects. Among them, the national Class I innovative biological drug 'Tai'ai' (Telitacicept) for the treatment of systemic lupus erythematosus (SLE) has been approved for marketing, bringing a major breakthrough in SLE treatment. The investigational RC48 (Disitamab Vedotin) is the first antibody-drug conjugate (ADC) new drug in China to enter human trials, used for the treatment of HER2-overexpressing cancers such as gastric cancer, urothelial carcinoma, and breast cancer, with the gastric cancer indication already launched in China. In addition, more than ten other innovative biological drugs are at various stages of R&D.
In the CDMO field, MabPlex is one of the few CDMO companies globally that can provide end-to-end services from ADC drug development to commercial production. It serves as the undertaking unit of Shandong Province's public service platform for antibody drug development and industrialization, is a national high-tech enterprise, and has established a branch in San Diego, USA, with the United States as its overseas center to radiate into the European and American markets.
The company has been recognized by government organizations at various levels as a National Torch Plan Key High-Tech Enterprise, a National (Enterprise) Innovative Drug Incubation Base, and a National Comprehensive New Drug R&D Technology Platform (Shandong) Industrialization Demonstration Enterprise, and has established a postdoctoral research workstation and a Shandong Province Academician Workstation and other innovation platforms.
The Group adheres to a people-oriented approach, values talent cultivation and team building, and provides employees with comprehensive benefits, broad development opportunities and platforms, and professional training and further education opportunities.
Rongchang Group welcomes you to join us! Join hands with Rongchang Group to improve the quality of life through science and create a bright future together!